Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd.
Your view on SLGL
Overview
What the company does, where it operates, and who runs it.
About Sol-Gel Technologies Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Moshe Arkin
- Headquarters
- 7 Golda Meir Street, Ness Ziona, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Moshe Arkin
- Headquarters
- 7 Golda Meir Street, Ness Ziona, IL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.
It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sol-Gel Technologies Ltd., and the rating behind it. SLGL last traded at $65.94; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sol-Gel Technologies Ltd.. Starting points for Sol-Gel Technologies Ltd.: EPS -$5.00, beta 1.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sol-Gel Technologies Ltd.. Sol-Gel Technologies Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sol-Gel Technologies Ltd.. Trailing twelve-month EPS for Sol-Gel Technologies Ltd. stands at -$5.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sol-Gel Technologies Ltd.. Sol-Gel Technologies Ltd. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sol-Gel Technologies Ltd. valued side by side against its closest peers. Sol-Gel Technologies Ltd. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sol-Gel Technologies Ltd., and how their positions are changing. At a $215.6M market value, institutional positions materially move Sol-Gel Technologies Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sol-Gel Technologies Ltd. executives and directors. Shares of Sol-Gel Technologies Ltd. have traded between $4.02 and $52.26 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sol-Gel Technologies Ltd.. Sol-Gel Technologies Ltd. is a $215.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sol-Gel Technologies Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sol-Gel Technologies Ltd.. Coverage tracks Sol-Gel Technologies Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.